2025 JPAD

/in , , , , , /by

2025 JPAD:

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer’s disease

2022 Frontiers in Neuroscience

/in , , , , /by

2022 Frontiers in Neuroscience:

 

ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease